To explore the incidence and influencing factors of anxiety and depression in multiple myeloma patients. METHODS: 509 patients with multiple myeloma in the Department of Hematology, General Hospital of Tianjin Medical University from September 2021 to March 2024 were selected for the study. The Generalized Anxiety Disorder Scale (GAD-7) and Depression Self-assessment Scale (PHQ-9) were used to assess the patients' anxiety and depression, and the Verbal Pain Rating Scale ( VPRS ) and Total Neuropathy Scale Reduced (TNSr) were used to assess the degree of pain and peripheral neuropathy. Clinical data such as patients' personal information, laboratory tests, DS/ISS/RISS staging, treatment line, and efficacy assessment were improved to analyze the incidence and influencing factors of anxiety and depression in patients with multiple myeloma. RESULTS: The incidence of anxiety and depression in patients with multiple myeloma was 22.2% and 31.4%, respectively . Comorbid pain and/or peripheral neuropathy were independent risk factors for the development of anxiety and depression and were significantly associated with the severity of both. CONCLUSION: The incidence of anxiety and depression in patients with multiple myeloma is high, and clinicians should pay attention to the rational intervention of pain and peripheral neurologic symptoms and the early assessment of emotional problems during the peri-therapeutic period of patients!
No relevant conflicts of interest to declare.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal